title: Are parkin patients particularly suited for deep-brain stimulation?
abstract: Patients with parkin mutations are known to have slower PD progression and a better response to levodopa at lower doses than patients with idiopathic Parkinson's disease. To determine the effects of deep brain stimulation (DBS) on such patients, we have compared the follow-up after surgery of 7 patients with one parkin mutation, 7 patients with two parkin mutations, and 39 patients without parkin mutations. Twelve to 24 months after neurosurgery, the daily doses of levodopa equivalent were significantly lower in patients with two parkin mutations, indicating that these patients benefit from DBS, and they might have more durable results.
authors.affiliation: INSERM, U679, Paris, France.
authors.forename: Ebba
authors.initials: E
authors.lastname: Lohmann
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Welter
authors.forename: Valérie
authors.initials: V
authors.lastname: Fraix
authors.forename: Paul
authors.initials: P
authors.lastname: Krack
authors.forename: Suzanne
authors.initials: S
authors.lastname: Lesage
authors.forename: Sophie
authors.initials: S
authors.lastname: Laine
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Tanguy
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Houeto
authors.forename: Valérie
authors.initials: V
authors.lastname: Mesnage
authors.forename: Pierre
authors.initials: P
authors.lastname: Pollak
authors.forename: Alexandra
authors.initials: A
authors.lastname: Durr
authors.forename: Yves
authors.initials: Y
authors.lastname: Agid
authors.forename: Alexis
authors.initials: A
authors.lastname: Brice
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D046690:Deep Brain Stimulation; D004409:Dyskinesia, Drug-Induced; D005260:Female; D005500:Follow-Up Studies; D005820:Genetic Testing; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009154:Mutation; D020734:Parkinsonian Disorders / Q000235:genetics* / Q000628:therapy*; D016896:Treatment Outcome; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein